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Introduction 
Amiodarone is a commonly used drug 
for the treatment of cardiac arrhythmias. It 
has a broad range of toxicity including 
photosensitivity, blue-gray discoloration of 
the skin, thyroid dysfunction, corneal 
deposits, abnormal liver function tests, and 
bone marrow suppression.1 Pulmonary 
toxicity is the most serious adverse effect of 
amiodarone. Treatment of amiodarone-
induced pulmonary toxicity includes 
discontinuation of the drug and initiation of 
glucocorticoid therapy in the majority of 
symptomatic patients.  This case of recurrent  
 
 
amiodarone toxicity was manifested by 
acute interstitial pneumonitis and diffuse 
alveolar hemorrhage after a rapid taper of 
glucocorticoids. 
 
Case Report 
A 60-year-old male patient with no 
previous lung disease was admitted to the 
hospital with dyspnea and hypoxemia of 
85% on room air.  On physical examination, 
he had bilateral late inspiratory rales 
involving two-thirds of the chest. His chest 
x-ray showed diffuse bilateral pulmonary 
infiltrates (see Figure 1). 
 
 
Figure 1.  PA chest x-ray showing diffuse interstitial 
infiltrates especially at the bases.    
Kansas Journal of Medicine 2010                                                                   Amiodarone Toxicity 
16 
 
The patient had no history of 
occupational pulmonary exposure or history 
of rheumatologic disorder or joint pain.  He 
was diagnosed with atrial fibrillation nine 
months prior to presentation and was started 
on amiodarone 200 mg daily at that time.  
After admission, his laboratory workup 
revealed normal blood counts and 
electrolytes. His brain natriuretic peptide 
(BNP) level was 150 pg per milliliter. A 2-D 
echocardiogram showed normal ejection 
fraction. There was no clinical or radiologic 
improvement after empiric antibiotics and 
treatment with diuretics.  
A high resolution computed tomography 
of the chest was performed and showed 
bilateral ground glass opacities associated 
with small bilateral effusions (see Figure 2).  
Amiodarone-induced hypersensitivity pneu-
monitis was suspected. Subsequently, 
amiodarone was stopped and treatment with 
glucocorticoids initiated.  
 
 
Figure 2.  High resolution CT scan of the 
lung demonstrating bilateral ground glass 
appearance more prominent in the right 
middle lobe.      
 
There was a significant clinical and 
radiologic improvement (see Figure 3) on a 
follow-up visit one month later. The 
glucocorticoids were tapered over two 
weeks, then stopped.  
One week after stopping glucosteroids, 
the patient complained of shortness of breath  
 
on minimal activity, rapidly worsening to 
occur also at rest.  He also complained of a 
dry cough that progressed over the next few 
days to mild hemoptysis. He again was 
hypoxic with bilateral rales on physical 
examination and his chest x-ray revealed 
bilateral infiltrates.  
 
 
Figure 3.  High resolution CT scan after 
steroid treatment showing almost 
complete resolution of the infiltrates. 
 
Bronchoscopy was performed and 
transbronchial biopsies were obtained from 
the right lower lobe. The pathology 
examination showed interstitial fibrosis with 
no evidence of vasculitis or neoplasm (see 
Figures 4 and 5). 
 Bronchoalveolar lavage in the right 
middle lobe yielded a progressively bloodier 
return.  Cytology of the fluid was negative 
for malignant cells and revealed numerous 
lipid-laden macrophages (index of 70%), 
characteristic of amiodarone toxicity.  A 
significant number of hemosiderin-laden 
macrophages (index of 41%) were present, 
confirming the diagnosis of alveolar 
hemorrhage. 
The patient was started on intravenous 
glucocorticoids. He significantly improved 
and was discharged home on prednisone 60 
mg daily with plans to follow-up for several 
months.   A follow-up examination after two 
weeks revealed clinical and radiologic 
amelioration. 
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Figure 4.  Transbronchial biopsy showing 
fibrosis (asterisk), lipid-laden macrophages 
(black arrows), and hemosiderin-laden 
macrophages (arrowheads). 
 
 
Figure 5. Transbronchial biopsy with hema-
toxylin and eosin stain. The arrows indicate 
macrophages with hemosiderin granules. 
 
Discussion 
Pulmonary toxicity secondary to 
amiodarone use occurs in 5-15% of 
patients.2 Pulmonary manifestations range 
from mild to severe and even fatal disease 
such as ARDS. The most common 
presentation is interstitial pneumonitis 
accounting for one-third of patients.3 
Interstitial pneumonitis usually is 
recognized after two or more months of 
therapy, especially in patients in whom the 
dose of amiodarone exceeds 400 mg per 
day. Cytology from bronchoalveolar lavage 
is characterized by mononuclear cells 
predominance and foamy alveolar 
macrophages. Type II cell hyperplasia and 
pulmonary fibrosis have been reported. 
Other manifestations include organizing 
pneumonia,4 eosinophilic pneumonia, and 
lung nodules.5 
Alveolar hemorrhage is a rare 
complication of amiodarone pulmonary 
toxicity.  Only a few cases were reported in 
a large study of 171 patients.4 Two other 
cases of alveolar hemorrhage secondary to 
amiodarone use also were reported.6 
 
 
 
Amiodarone is a highly lipophilic drug 
that avidly binds to adipose tissues, resulting 
in a large distribution volume and a 
prolonged half-life reaching 180 days.7 
Given the high accumulation in adipose 
tissue, pulmonary toxicity may progress 
despite drug discontinuation. Treatment 
includes stopping the offending drug with 
initiation of glucocorticoid therapy in severe 
cases. Prednisone at 40 to 60 mg daily is 
recommended with slow tapering, as 
tolerated, over two to six months.  Despite 
the slow tapering, cases of recurrent 
pulmonary intoxication may occur.8 
In our case, the rapid tapering of 
prednisone may have been responsible for 
the acute recurrence of a more severe form 
of interstitial pneumonitis with evidence of 
diffuse alveolar hemorrhage.  The patient's 
elevated body mass index suggested a high 
volume of distribution of amiodarone which 
might explain the severity of the recurrent 
disease. This case emphasizes the 
importance of slow tapering of 
glucocorticoids following amiodarone-
induced lung injury.  
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